Clinical Trial Update: Sorafenib With TACE to Treat Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial update on combining sorafenib with transarterial chemoembolization (TACE) for hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: University of Bern | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: COMPLETED